The company has projected Rs. 5,630 crores of investment and to provide employment to 6,350 people in three phases over a period of eight years
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
Singhal brings a powerful blend of operational excellence, investor acumen, and visionary thinking
Kushwaha previously served as Chief Digital & Information Officer at Jubilant Ingrevia Limited
This certification validates the plant’s robust capabilities in manufacturing a wide range of sterile dosage forms
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
Deepak has around 25 years of work experience with reputed companies viz. UPL Group, Teva Group, AkzoNobel India, Ranbaxy Laboratories, and Dr. Reddy’s Laboratories
Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution
The company has made an investment of Rs. 565.40 crore in DRL Russia for a total equity stake of 45.19%
Prasad has played a key role in shaping Dr. Reddy’s into a globally respected organisation
Subscribe To Our Newsletter & Stay Updated
